[1]
Dodd S,Berk M, Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert review of neurotherapeutics. 2008 Sep; [PubMed PMID: 18759541]
[2]
Wilson MP,Pepper D,Currier GW,Holloman GH Jr,Feifel D, The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. The western journal of emergency medicine. 2012 Feb; [PubMed PMID: 22461918]
[3]
Markowitz JD,Narasimhan M, Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont (Pa. : Township)). 2008 Oct; [PubMed PMID: 19724721]
[4]
Attia E,Steinglass JE,Walsh BT,Wang Y,Wu P,Schreyer C,Wildes J,Yilmaz Z,Guarda AS,Kaplan AS,Marcus MD, Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial. The American journal of psychiatry. 2019 Jun 1; [PubMed PMID: 30654643]
[5]
Adel N, Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. The American journal of managed care. 2017 Sep [PubMed PMID: 28978206]
[6]
Tollens F,Gass N,Becker R,Schwarz AJ,Risterucci C,Künnecke B,Lebhardt P,Reinwald J,Sack M,Weber-Fahr W,Meyer-Lindenberg A,Sartorius A, The affinity of antipsychotic drugs to dopamine and serotonin 5-HT{sub}2{/sub} receptors determines their effects on prefrontal-striatal functional connectivity. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2018 Jul 10 [PubMed PMID: 30006253]
[7]
Na Takuathung M,Hanprasertpong N,Teekachunhatean S,Koonrungsesomboon N, Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis. Acta psychiatrica Scandinavica. 2018 Aug 15 [PubMed PMID: 30112761]
[8]
Mauri MC,Paletta S,Di Pace C,Reggiori A,Cirnigliaro G,Valli I,Altamura AC, Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical pharmacokinetics. 2018 Jun 19 [PubMed PMID: 29915922]
[9]
Meyers KJ,Upadhyaya HP,Landry JL,Chhabra-Khanna R,Falk DM,Seetharama Rao B,Jones ME, Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. BJPsych open. 2017 Jul [PubMed PMID: 28811926]
[10]
Hou PH,Chang GR,Chen CP,Lin YL,Chao IS,Shen TT,Mao FC, Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice. Iranian journal of basic medical sciences. 2018 May [PubMed PMID: 29922430]
[11]
Huang M,Yu L,Pan F,Lu S,Hu S,Hu J,Chen J,Jin P,Qi H,Xu Y, A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients. Progress in neuro-psychopharmacology [PubMed PMID: 29097257]
[12]
Nicol GE,Yingling MD,Flavin KS,Schweiger JA,Patterson BW,Schechtman KB,Newcomer JW, Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. JAMA psychiatry. 2018 Aug 1 [PubMed PMID: 29898210]
[13]
Li R,Ou J,Li L,Yang Y,Zhao J,Wu R, The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance. Frontiers in pharmacology. 2018 [PubMed PMID: 29713286]
[14]
Carrillo JA,González JA,Gervasini G,López R,Fernández MA,Núñez GM, Thrombocytopenia and fatality associated with olanzapine. European journal of clinical pharmacology. 2004 Jun [PubMed PMID: 15150680]
[15]
Lander M,Bastiampillai T, Neutropenia associated with quetiapine, olanzapine, and aripiprazole. The Australian and New Zealand journal of psychiatry. 2011 Jan; [PubMed PMID: 21058927]
[16]
Kim HM,Chiang C,Kales HC, After the black box warning: predictors of psychotropic treatment choices for older patients with dementia. Psychiatric services (Washington, D.C.). 2011 Oct [PubMed PMID: 21969648]
[17]
Polasek TM,Tucker GT,Sorich MJ,Wiese MD,Mohan T,Rostami-Hodjegan A,Korprasertthaworn P,Perera V,Rowland A, Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British journal of clinical pharmacology. 2018 Mar [PubMed PMID: 29194718]
[18]
Urban AE,CubaĆa WJ, Therapeutic drug monitoring of atypical antipsychotics. Psychiatria polska. 2017 Dec 30 [PubMed PMID: 29432503]
[19]
Hopkins LE,Sunkersing J,Jacques A, Too many pills to swallow: A case of a mixed overdose. Journal of the Intensive Care Society. 2017 Aug [PubMed PMID: 29118840]
[20]
Palenzona S,Meier PJ,Kupferschmidt H,Rauber-Luethy C, The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. Journal of toxicology. Clinical toxicology. 2004 [PubMed PMID: 15083933]
[21]
Tan HH,Hoppe J,Heard K, A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. The American journal of emergency medicine. 2009 Jun [PubMed PMID: 19497468]
[22]
Pourahmad J,Salimi A,Razian M, Analysis of Toxicity Effects of Buspirone, Cetirizine and Olanzapine on Human Blood Lymphocytes: in Vitro Model. Current clinical pharmacology. 2018 May 15 [PubMed PMID: 29766823]
[23]
Yeisen RA,Joa I,Johannessen JO,Opjordsmoen S, Use of medication algorithms in first episode psychosis: a naturalistic observational study. Early intervention in psychiatry. 2016 Dec [PubMed PMID: 25588989]